Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brachytherapy with or without triptorelin for recurrent prostate cancer after prior radiotherapy
2010-019158-41Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Jan 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triptorelin in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Biochemical failure-free survival. Started Jan 2012; status: terminated.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-019158-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019158-41.